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MiR-449a suppresses the epithelial-
mesenchymal transition and metastasis of
hepatocellular carcinoma by multiple targets
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Abstract
Background: Increasing evidence indicates that Epithelial–mesenchymal transition (EMT) can be regulated by
microRNAs (miRNAs). MiR-449a is a liver abundant miRNA. However, the role of miR-449a in the metastasis of
hepatocellular carcinoma (HCC) remains largely unknown.
Methods: The expression levels of miR-449a were first examined in HCC cell lines and tumour tissues by
real-time PCR. The in vitro and in vivo functional effect and underlying molecular mechanisms of miR-449a
were examined further.
Results: In the present study, we found that miR-449a was significantly decreased in HCC cells and tissues,
especially in those with the portal vein tumor thrombus. In HCC cell lines, stable overexpression of miR-449a
was sufficient to inhibit cell motility in vitro, and pulmonary metastasis in vivo. In addition, ectopic overexpression of
miR-449a in HCC cells promoted the expression of epithelial markers and reduced the levels of mesenchymal markers.
Further studies revealed that the reintroduction of miR-449a attenuated the downstream signaling of Met, and
consequently reduced the accumulation of Snail in cell nucleus by targeting the 3’-untranslated regions (3’-UTR) of FOS
and Met.
Conclusions: Our data highlight an important role of miR-449a in the molecular etiology of HCC, and implicate
the potential application of miR-449a in cancer therapy.
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Background
It is known that invasion and metastasis, two of the
most important hallmarks of malignant tumours, are the
foremost fatal factors for human cancers. Identification
of invasive and/or metastatic factors and an under-
standing of the underlying molecular mechanisms
may provide novel targets for cancer therapy. Increas-
ing evidence indicates that epithelial–mesenchymal
transition (EMT) is a key event in tumor invasion
and metastasis. During EMT, a morphological change
from epithelial-like to mesenchymal-like appearance is
accompanied by loss of cell-cell adhesion and activa-
tion of mesenchymal markers, such as N-cadherin,
fibronectin and vimentin, as well as increased motility
of tumor cells, which consequently facilitates tumor
metastasis [1].
miRNAs provide functions essential for diverse bio-
logical processes by inducing translational inhibition and/
or mRNA degradation of protein-coding genes [2, 3].
Deregulation of miRNA have been observed in various
diseases, including cancer [4]. To date, more and more
reports have indicated that a few miRNAs suppress (for
example, the miR-200 family, miR-124, and miR-148a)
[5–8] or promote (for example, miR-24 and miR-130b)
[9, 10] EMT and tumor metastasis. Although some
miRNAs (for example, miR-122, miR-26a, miR-331-3p
and miR-216a/217) [11, 12] have been identified to
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regulate EMT in liver cancer, the role of miRNAs in the
EMT of HCC deserved further investigation.
It has been reported that miR-449a is downregulated
in multiple maglignancies. It inhibits growth of ovarian
[13], endometrial [14] and prostate cancer cells [15],
bladder cancer [16] and retinoblastoma [17], promotes
apoptosis of colorectal and gastric adenocarcinoma
cancer [18, 19], represses migration and invasion of non-
small cell lung cancer [20], and also enhances the che-
mosensitivity to cisplatin in gastric cancer [21] and
radiosentivity in lung adenocarcinoma [22]. The identi-
fied targets of miR-449a include HDAC [23], CDK6 and
CDC25A [14, 24], BCL2 [18], cyclinD1 [21], E2F3 [25],
C-MET [20], Notch1 and KLF4 [26] and androgen re-
ceptor [15]. These findings indicate that miR-449a may
function as a potential tumor suppressor through diverse
mechanisms. It was reported that the expression of miR-
449a in HCC was inhibited by Histone deacetylases to
tumorigenesis [27]. However, the role of miR-449a in the
metastasis of hepatocellular carcinoma (HCC) remains
largely unknown. In the present study, we showed that
miR-449a displayed more pronounced reduction in HCC
tissues with the portal vein tumor thrombus (PVTT).
The restoration of miR-449a expression significantly re-
pressed the in vitro migration and invasion, and in vivo
pulmonary metastasis of hepatoma cells. Subsequent
mechanism studies revealed that miR-449a attenuated
EMT program by directly targeting FOS and Met. More-
over, the reintroduction of miR-449a attenuated the
downstream signaling of Met, like activated phosphoryl-
ation of AKT-Ser473 and inhibitory phosphorylation of
GSK-3α/β-Ser21/9, and consequently reduced the accu-
mulation of Snail in cell nucleus, a transcription factor
that promotes EMT. These findings provided novel
mechanistic insights into the role of miR-449a in EMT
and metastasis.
Methods
Tissue specimens and cell cultures
Normal liver tissues were collected from 18 patients
who underwent resection of hepatic hemangiomas, and
66 HCC tissues were obtained from at the Cancer
Center, Sun Yat-Sen University and Guangdong Provin-
cial People’s Hospital (Guangzhou, China). All cases
were histologically confirmed. None of the patients had
received local or systemic anticancer treatment before
the surgery. Written-informed consent was obtained
from each patient, and the study was approved by the
Institute Research Medical Ethics Committee of Sun
Yat-Sen Memorial Hospital.
Four HCC cell lines (Hep3B, Bel-7402, SMMC-7721
and MHCC-LM9) were cultured in RPMI1640 medium
with 10 % newborn calf serum. Another two HCC cell
lines, Huh7 and HepG2, and normal hepatic cell line
LO2, and 293FT, were maintained in Dulbecco’s modi-
fied Eagle’s medium supplemented with 10 % fetal
bovine serum (FBS).
RNA isolation and quantitative real-time PCR
Total RNA from cell lines and tissues was extracted with
TRIzol reagent (Invitrogen, Carsbad, CA). cDNA was
synthesized with the PrimeScript RT reagent Kit (Pro-
mega, Madison, WI). Real-time PCR was carried out
using an ABI 7900HT Fast Real-time PCR system
(Applied Biosystems, Foster City, CA) according to the
manufacturer’s recommended conditions. The primer
has been showed in Additional file 1: Table S1.
Lentivirus production and HCC cell infection
Virus particles were harvested 48 h after pCDH-CMV-
miR-449a-coGFP or pCDH-CMV-coGFP (System Biosci-
ences, CA) transfection with the packaging plasmid
pRSV/REV, pCMV/VSVG and pMDLG/pRRE into
293FT cells by using Lipofectamine 2000 reagent (Invi-
trogen). Lentivirus-miR-449a-coGFP and lentivirus-miR-
ctr-coGFP were condensed and purified for 108 MOI/
200 μl. Next, LM9 and Huh-7 HCC cells were infected by
lent-miR-449a and lent-miR-control, respectively, to
construct the stable miR-449a-expressing and control
HCC cells.
Oligonucleotide transfection
MiR-449a inhibitor was synthesized by Genepharma
(Shanghai, China). The sequence of siRNA FOS mRNA
was 5’-CUGAGAAGCCAAGACUGAGUU-3’ (sense) and
5’-CUCAGUCUUGGCUUCUCAGUU-3’ (antisense). The
sequences of the Met siRNA were 5’-GUCAUAGGAA
GAGGGCAUUTT-3’ (sense), and 5’-AAUGCC CUCUU
CCUAUGACTT-3’ (antisense), which were synthesized by
Ribobo (Guangzhou, China). Oligonucleotide transfec-
tion was performed with Lipofectamine 2000 reagents
(Invitrogen).
Luciferase reporter assay
The putative miR-101 binding site at the 3’-UTR of FOS
and Met mRNAs was cloned downstream of the cyto-
megalovirus (CMV) promoter in a pMIR-REPORT vector
(Ambion). Two mutant constructs were generated by
either deletion or mutations. The firefly luciferase con-
struct was cotransfected with a control Renilla luciferase
vector into LM9 cells in the presence of either lent-miR-
449a or lent-miR-control. Dual luciferase assay (Promega)
was performed 48 hours after transfection. The experi-
ments were performed independently in triplicate.
Colony formation assay
Twenty-four hours after infection, 200 or 500 infected
cells were placed in a fresh six-well plate and maintained
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in RPMI1640 and Dulbecco’s modified Eagle’s medium
containing 10 % FBS for 2 weeks. Colonies were fixed
with methanol and stained with 0.1 % crystal violet in
20 % methanol for 15 min.
Wound healing and invasion assays
Cell migration was assessed by measuring the movement
of cells into a scraped, acellular area created by a 200-μl
pipette tube, and the spread of wound closure was
observed after 48 hours and photographed under a
microscope. We measured the fraction of cell coverage
across the line for migration rate. For invasion assays,
105 cells were added to a Matrigel™ Invasion Chamber
(BD Biosciences, Becton Dickson Labware, Flanklin
Lakes, NJ) present in the insert of a 24 well culture
plate. Fetal bovine serum was added to the lower cham-
ber as a chemoattractant. After 48 hours, the non-
invading cells were gently removed with a cotton swab.
Invasive cells located on the lower side of the chamber
were stained with crystal violet, air dried and photo-
graphed. For colorimetric assays, the inserts were
treated with 150 μl 10 % acetic acid and the absorbance
was measured at 560 nm using a spectrophotometer
(Spectramax M5).
Western blot analysis and immunofluorescence (IF)
Proteins were separated on SDS–PAGE and transferred
to nitrocellulose membrane (Bio-Rad). The membrane
was blocked with 5 % non-fat milk and incubated with
the corresponding mouse anti-FOS, Met, E-cadherin,
α-catenin, β-catenin, N-cadherin, fibronectin, vimentin
(BD Biosciences, 1:1000 dilution), α-tubulin (Santa
Cruz Biotechnology, Santa Cruz, CA, 1:1000 dilution),
snail and GAPDH (Cell signaling Technology, Beverly,
MA, 1:500 dilution) monoclonal antibodies. The pro-
teins were detected with enhanced chemiluminescence
reagents.
For the IF studies, cells were fixed with 4 % parafor-
maldehyde in phosphate-buffered saline and perme-
abilized with 0.2 % Triton X-100 in phosphate-buffered
saline. Fixed cells were incubated with 1:2000 fluores-
cein isothiocyanate–conjugated phalloidin (Sigma, St.
Louis, MO) or antibodies as indicated. Cells were coun-
terstained with 4, 6-diamidino-2-phenylindole (DAPI)
(Calbiochem, San Diego, CA) and imaged with a
confocal laser-scanning microscope (Olympus FV1000,
Tokyo, Japan).
In vivo metastasis assay
MiR-control-Huh7 or miR-449a-Huh7 cells (2 × 106) was
suspended in 30 ml of PBS/Matrigel (1:1) and then
implanted under the capsule of the left hepatic lobe of
male BALB/c athymic nude mice at 4–5 weeks of age.
The animals were killed and examined 38 days after
tumor cell implantation. The liver and the lungs were
removed and fixed with phosphate-buffered formalin.
All the procedures are accordant with the Guide for the
Care and Use of Laboratory Animals (NIH publications
Nos. 80–23, revised 1996) and the Institutional Ethical
Guidelines for Animal Experiments.
Statistical analysis
Statistical analysis was performed using a SPSS software
package (SPSS Standard version 16.0, SPSS Inc.). Differ-
ences between variables were assessed by the c2 test or
Fisher’s exact test. For survival analysis, we analysed all
patients with HCC by KaplaneMeier analysis. A log rank
test was used to compare different survival curves.
Multivariate survival analysis was performed on all
parameters that were found to be significant in univari-
ate analysis using the Cox regression model. Data
derived from cell line experiments are presented as
mean ± SE and assessed by a Two-tailed Student’s t test.
P values of <0.05 were considered significant.
Results
Down-regulation of miR-449a is a frequent event in HCC
patients with PVTT
To explore the roles of miR-449a in the development of
HCC, the level of miR-449a was analyzed in 18 normal
livers and 77 HCC tissues. Compared with normal tis-
sues, the expression of miR-449a significantly decreased
in HCCs. Further, those tumor tissues with the PVTT
(11 samples) displayed more significantly reduction in
miR-449a (Fig. 1a), suggesting that there was the poten-
tial correlation between miR-449a downregulation and
HCC metastasis.
Low-level expression of miR-449a is associated with an
aggressive and/or poor prognostic phenotype of HCCs
To further investigate the clinicopathological and prog-
nostic significance of miR-449a levels in patients with
HCC, the levels of miR-449a in a large cohort of 77
HCC tissues were examined by real-time PCR. The
median value of all 77 HCC samples was chosen as the
cut-off point for separating tumours with low-level
expression of miR-449a from high-level expression miR-
449a tumours, thus 38/77 (49.4 %) HCCs had low-level
expression of miR-449a, while 39/77 (50.6 %) HCCs had
high-level expression of miR-449a (Table 1). Correlation
analysis showed that low-level expression of miR-449a in
HCCs was significantly associated with a more aggres-
sive tumour phenotype (p < 0.05, Table 1). Kaplan-Meier
analysis revealed that low-level expression of miR-449a
was associated with short disease-free survival of pa-
tients with HCC (p < 0.001, Fig. 1b, Table 1). Further
multivariate Cox regression analysis indicated that low-
level expression of miR-449a is an independent prognostic
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factor for poor survival of patients with HCC (p < 0.001,
Additional file 2: Table S2, Fig. 1b).
Exogenetic overexpression of miR-449a suppresses HCC
cell-line colony formation, migration and invasion in vitro
and metastatic potential of HCC cell lines in vivo
To further investigate the effect of miR-449a on the
metastasis of tumor cells, the expression levels of miR-
449a were examined by real-time PCR in seven hepato-
cellular cell lines. The results showed that all six HCC
cell lines (Hep3B, Bel-7402, SMMC-7721, MHCC-LM9,
Huh7, HepG2) had lower levels of miR-449a expression
than that in the normal hepatic cell line LO2. In
addition, the metastatic HCC cell line LM9 showed the
lowest levels of miR-449a (Fig. 1c).
The above observations prompted us to explore the
potential biological function of miR-449a in HCC
tumourigenesis and/or progression. Initially, the capacity
of colony formation was evaluated in HCC cell lines
(Huh7 and LM9) that were infected with miR-449a,
miR-control. We found that miR-449a-infected cells had
much fewer and smaller colonies than those in the miR-
control-infected cells (Fig. 2a), indicating a growth-
inhibitory role of miR-449a in HCC cells.
Next, the effect of miR-449a on invasive capacity of
HCC cells was characterised by the wound-healing and
Matrigel invasion assays. The results showed that exoge-
netic overexpression of miR-449a caused a suppression
of cell migration in the LM9 and Huh7 cell lines using a
wound-healing assay (Fig. 2b). Matrigel invasion assays
demonstrated that exogenetic overexpression of miR-
449a markedly reduced invasiveness of LM9 and Huh7
cell lines (Fig. 2c, p < 0.05).
To confirm the in vivo metastasis-inhibitive function
of miR-449a, an orthotopic HCC mouse model was
employed. Huh7 cell that stably expressed miR-449a
(miR-449a-Huh7) and its control line (miR-control-
Huh7) were, respectively, implanted under liver capsule.
Thirty-eight days after implantation, cell growth in the
liver and the lung was assessed. First, the size of the
primary tumour nodules in the liver was examined.
Tumor incidence was 56.25 % (9/16) in the miR-control-
Huh7-injected mice and 18.75 % (3/16) in the miR-
449a-Huh7 group. And we found that the tumour sizes
(tumour diameters) were significantly decreased in the
Fig. 1 The levels of mature miR-449a expression in human HCC cell lines and tissues by real-time PCR. a miR-449a expression was reduced in
HCC tissues with the PVTT. The levels of miR-449a in normal livers (n = 18), HCC tissues without the PVTT (n = 66) and with the PVTT (n = 11) were
detected by qPCR and were then normalized to the expression of RNU6B to yield the relative miR-449a levels for individual sample. The median
level of miR-449a in all HCC tissues was set as cut-off. Mann–Whitney U-test was applied to compare the differences in the miR-449a expression
between the indicated cohorts. *P < 0.05, ***P < 0.001. b KaplaneMeier analysis for survival of patients with HCC as a function of miR-449a levels.
Probability of patient survival, high-expression of miR-449a, n = 39; low-expression of miR-449a, n = 38 (p < 0.001). c Expression levels of miR-449a
were examined by real-time PCR in LO2 cells and six HCC cell lines. Experiments were performed three times. Data are presented as means ± SE
(p < 0.0001, independent t test)
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miR-449a group compared with that in the miR-control
group (p < 0.01, Fig. 2d). To explore the role of miR-449a
in tumour metastasis, we examined the number and the
size of the tumor metastatic nodules under a microscope
in the liver and in the lung. As shown in Fig. 2e, the num-
ber of pulmonary metastatic nodules was clearly de-
creased in the miR-449a group compared with that in
miR-control group (9/16 vs 3/16 mice, p = 0.016, Fig. 2e,
Table 2), but comparable rate of intrahepatic metastasis
(3/16 vs 3/16 mice, p = 0.93, Fig. 2e). Collectively, these
results indicate that miR-449a possesses metastasis-
suppressive activity and its downregulation may facilitate
the metastasis of HCC.
Silencing endogenous miR-449a promotes cell motility
and induces the EMT phenotype
Because cell motility is an important factor regulating
cancer invasion and metastasis, the effect of miR-449a
Table 1 Correlation of plasma miR-449a expression with patients’ clinicopathologic variables in human hepatocellular carcinomas
Variable miR-449a
All cases Low expression High expression P value*
Age (years) 0.710
≤50a 31 14 (45.2 %) 17 (54.8 %)
>50 46 24 (52.2 %) 22 (47.8 %)
Sex 0.768
Male 67 34 (50.7 %) 33 (49.3 %)
Female 10 4 (40.0 %) 6 (60.0 %)
Etiology 0.702
HBV 67 32 (47.8 %) 35 (52.2 %)
None 10 6 (60.0 %) 4 (40.0 %)
AFP (ng/ml) 0.052
≤20 44 17 (38.6 %) 27 (61.4 %)
>20 33 21 (63.6 %) 12 (36.4 %)
Liver cirrhosis 0.307
Yes 55 30 (54.5 %) 25 (45.5 %)
No 22 8 (36.4 %) 14 (63.6 %)
Tumor size (cm) 0.016
≤5 43 16 (37.2 %) 27 (62.8 %)
>5 34 22 (64.7 %) 12 (35.3 %)
Tumor multiplicity 0.014
Single 47 18 (38.3 %) 29 (61.7 %)
Multiple 30 20 (66.7 %) 10 (33.3 %)
Differentiation
Well 10 3 (30.0 %) 7 (70.0 %) 0.137
Moderate 43 25 (58.1 %) 18 (41.9 %)
Poor 20 7 (35.0 %) 13 (65.0 %)
Undifferentiated 4 3 (75.0 %) 1 (25.0 %)
Stage
I 7 1 (14.3.0 %) 6 (85.7 %) 0.001
II 23 7 (30.4 %) 16 (69.6 %)
III 31 15 (48.4 %) 16 (51.6 %)
IV 16 15 (93.8 %) 1 (6.2 %)
Distant metastasis 0.014
M1 9 8 (88.9 %) 1 (11.1 %)
MX 68 30 (44.1 %) 38 (55.9 %)
*Chi-square test; aMean age; HBV, hepatitis B virus; AFP indicates alpha-fetoprotein.
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on cell motility was characterized by Matrigel invasion
and wound healing assays. At first, because LO2 cell
endogenously expresses the high miR-449a by the real-
time PCR (Fig. 1c), we transfected LO2 cells with the
anti-miR-449a and examined the cell motility. The Matri-
gel invasion assay showed that the invasiveness of the
anti-miR-449a-LO2 cells was significantly higher than
anti-miR-NC-LO2 cells (P < 0.001, Fig. 3a). Similarly, the
Fig. 2 Exogenetic expression of miR-449a suppresses hepatocellular carcinoma cell invasion in vitro and reduces metastasis in vivo. a Effect of miR-449a
on colony formation of the HCC cell line. Two hundred or 500 miR-124-infected Huh7 and LM9 cells were plated and a colony formation
assay carried out. Representative results of colony formation of mock, miR-control-lentivirus-infected, miR-449a-lentivirus-infected Huh7 and
LM9 cells. The results were reproducible in three independent experiments. b The wound-healing assay showed different cell motilities in
miR-control-LM9, miR-449a-LM9, miR-control-Huh7 and miR-449a-Huh7 cells. The ectopic expression of miR-449a obviously inhibited the
migration of LM9 and Huh7 cells. c Cell invasion was evaluated using a Matrigel invasion chamber. LM9 and Huh7 cells were infected by
miR-control-lentivirus and miR-449a-lentivirus, respectively. All cells were subjected to a Matrigel invasion assay with fetal bovine serum as
chemoattractant. Invasive cells were fixed and stained with crystal violet. The inserts were treated with 10 % acetic acid and the absorbance was measured.
Both overexpression of miR-449a clearly inhibited the invasion of LM9 and Huh7 cells. Data are the means ± SD of three independent
experiments. *p < 0.05, **p < 0.01. Scale bar: 100 mm. d Up, representative liver, treatments indicated. Down, the sizes of primary tumours in livers of
mice, thirty-eight days after implantation of miR-control-Huh7 cells (average size, ± SE, 6.199 ± 1.63 mm) and miR-449a-Huh7 cells (average size, ± SE,
2.50 ± 0.79 mm). e The restoration of miR-449a inhibited the pulmonary metastases of HCC cells in vivo. miR-449a-Huh7 (Huh7 cells with stable
expression of miR-449a) and miR-control-Huh7(control cells) were inoculated under the capsules of the left hepatic lobes of nude mice.
Hematoxylin-eosin (HE) staining was performed on the serial sections of paraffin-embedded lung tissues (left and middle panels). Scale
bar, ×100
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wound-healing assay showed that cell migration at the
edge of exposed regions was remarkably faster in anti-
miR-449a-transfected cells than in anti-miR-NC cells
(Fig. 3b). The data indicated that anti-miR-449a enhanced
the cell motility.
And we found that the anti-miR-NC-LO2 cells main-
tained highly organized cell-cell adhesion. However,
when plated at the same cell density, anti-miR-449a-
LO2 cells exhibited a cell scattering phenomenon and
loss of cell-cell contact, accompanied by the spindle-
shaped, fibroblastic morphology (Fig. 3c). The morpho-
logical changes indicated that these cells may undergo
EMT. To further demonstrate this phenotype, the effect
of miR-449a on EMT was investigated by western
blot and IF. In anti-miR-449a-LO2 cells, expression of
E-cadherin, α-catenin and β-catenin decreased. On the
other hand, all mesenchymal markers tested, including
fibronectin, N-cadherin, vimentin, were elevated in anti-
Table 2 miR-449a inhibited pulmonary metastasis
Groups Metastasis P values
- +
Huh7-miR-control 7 9 0.016
Huh7-miR-449a 13 3
The difference in the pulmonary metastatic rates between the miR-control-Huh7
and miR-449a-Huh7 was analyzed by Fisher’s exact test
Fig. 3 Silencing endogenous miR-449a promotes cell motility and induces the EMT phenotype. a The invasive properties of the LO2 cells transfected
with between anti-miR-NC and anti-miR-449a were analyzed by an invasion assay using a Matrigel™ Invasion Chamber. Migrated cells were plotted as
the average number of cells per field of view from 3 different experiments, as described in Methods. b Anti-miR-449a- LO2-transfected cells showed
higher motility in a wound-healing assay. 48 hours posttreatment. c Cell morphyology of anti-miR-NC- LO2 and anti-miR-449a- LO2 cells. d Expressions
of epithelial markers α-catenin, β-catenin and mesenchymal markers fibronectin, N-cadherin and vimentin were compared by western blot analysis
between anti-miR-NC-LO2 and anti-miR-449a- LO2 cells. α-tubulin was used as a loading control. e IF was used to compare expression level/pattern of
epithelial markers and mesenchymal markers between anti-miR-NC-LO2 and anti-miR-449a-LO2 cells. Epithelial markers α-catenin, β-catenin (red signal)
were downregulated in anti-miR-449a cells; mesenchymal markers fibronectin, N-cadherin and vimentin (red cytoplastic signal) were upregulated in
anti-miR-449a cells
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miR-449a-LO2 cells (Fig. 3d). These data reinforced that
miR-449a overexpression may inhibit EMT. The Western
blot results were confirmed by IF analysis (Fig. 3e). In
particular, the mesenchymal marker fibronectin was com-
pletely undetectable in LO2-anti-miR-NC cells, whereas
anti-miR-449a-LO2 cells showed positive staining of fibro-
nectin in the cytoplasm. In addition, vimentin intermedi-
ate filaments localized in a concentrated and polarized
pattern in anti-miR-NC-LO2 cells; however, in anti-miR-
449a-LO2 cells a network of vimentin intermediate fila-
ments was clearly visible. Taken together, these results
strongly suggested that silencing endogenous miR-449a
induces the EMT phenotype.
Overexpression of miR-449a inhibits HCC cell and in vivo
EMT
Since EMT is well known to be involved in invasion and
metastasis of cancer cells, we asked whether or not the
levels of miR-449a in HCC cells can reverse the EMT
induction. We assessed the epithelial and mesenchymal
markers by western blot in miR-control and miR-449a-
overexpressing LM9 and Huh7 cells. The expression
levels of three epithelial markers (E-cadherin, a-catenin
and b-catenin) increased (Fig. 4a), while the levels of
three mesenchymal markers (fibronectin, N-cadherin
and vimentin) decreased. On the other hand, loss-of-
function analyses in HepG2 cells showed that the inhib-
ition of miR-449a with antimiR-449a reduced E-cadherin
expression and elevated N-cadherin level (Fig. 4b and c).
These results indicated that overexpression of miR-449a
represses the EMT phenotype of Huh7 and LM9 cells.
Furthermore, IHC staining demonstrated that the
tumors in the livers of mice originating from miR-
449a-Huh7 cells had decreased expression of fibronec-
tin, N-cadherin and vimentin and increased expression
of E-cadherin, α-catenin and β-catenin, compared with
that from miR-control-Huh7 cells (Fig. 4d). These data
showed that overexpression of miR-449a inhibited the
EMT of Huh7 cells both in vitro and in vivo.
MiR-449a directly targets FOS and Met 3’-UTR
We next explored the molecular mechanisms respon-
sible for the EMT and metastasis-suppressive effect of
miR-449a. Putative miR-449a targets were predicted
using target prediction programs, miRanda and TargetS-
can. Our analysis revealed that FOS and Met were two
potential targets of miR-449a. The 3’-UTR of FOS and
Met mRNA contains a complementarysite for the seed
region of miR-449a (Fig. 5a). To verify whether or not
FOS and Met are direct targets of miR-449a, FOS and
Met 3’-UTRs (Fig. 5a) and two mutants containing the
miR-449a binding sites were cloned downstream of the
luciferase open reading frame. These reporter constructs
were used to cotransfect HCC LM9 cells. Increased
expression of miR-449a upon infection, significantly
affected the luciferase expression, measured by the
luciferase activity. Conversely, when we performed lucifer-
ase assays using a plasmid harbouring the 3’-UTR of FOS
and Met mRNAs, in which the binding sites for miR-449a
were inactivated by site-directed mutant genesis, the lucif-
erase activity of mutant reporters were unaffected by the
simultaneous infection of miR-449a (Fig. 5b).
To determine if miR-449a affects FOS and Met ex-
pression in the HCC intracellular environment, we ana-
lysed the changes of FOS and Met expression in HCC
cell line LM9 after miR-449a overexpression. Using real-
time-PCR, we found that the mRNA levels of both FOS
and Met were dramatically reduced in miR-449a-Huh7
cells, as compared with that in miR-control-Huh7 cells
(Fig. 5c). Meanwhile, the protein levels of FOS and Met
were also substantially decreased after ectopic overexpres-
sion of miR-449a in Huh7 cell lines as evidenced by west-
ern blot assays (Fig. 5d). On the other hand, knock down
of miR-449a by 20-O-me-anti-miR-449a in HepG2 cells
increased protein levels of FOS and Met (Fig. 5e).Taken
together, these data support the bioinformatics predic-
tions indicating FOS and Met 3’-UTRs as direct targets
of miR-449a.
To determine whether or not FOS and Met are in-
volved in miR-449a-inhibited invasion and migration, we
first transfected Huh7 and LM9 cells with siFOS or
siMet. The results showed that knockdown of FOS and
Met by siRNA suppressed the invasive ability of Huh7
and LM9 cells (Additional file 3: Figure S1). Addition-
ally, introduction of miR-449a had a greater inhibitory
effect on cell migration and invasion than that of knock-
down of FOS and Met alone. So these data indicate that
FOS and Met are involved in miR-449a-inhibited inva-
sion and migration. At the same time, we also confirmed
that Notch1 is the another target of miR-449a in HCC
(Additional file 4: Figure S2).
MiR-449a levels are inversely correlated with mRNA
expression of FOS and Met in HCC tissues
We further examined the mRNA expression of FOS and
Met in 77 cases of HCC tissues. A significant inverse
correlation between the levels of miR-449a and mRNA
expression of FOS and Met was evaluated in our HCC
cohorts. And low levels of miR-449a were more likely to
be observed in HCCs with high expression of FOS or
Met mRNA (P < 0.01, Additional file 5: Table S3).
MiR-449a represses Snail signaling and its nuclear
accumulation by directly targeting FOS and Met
It is known that the resultant nuclear accumulation of
Snail transactivates the expression of mesenchymal
markers and inhibits the transcription of E-cadherin
[28]. And Met signaling activates AKT and abrogates
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GSK-3α/β activity, which in turn causes the reduced
phosphorylation and ubiquitination of Snail [29]. There-
fore, we investigated whether miR-449a repressed AKT/
GSK-3α/β/Snail signaling cascades. The overexpression
of miR-449a attenuated the activated phosphorylation of
AKT-Ser473 and the inhibitory phosphorylation of GSK-
3α/β-Ser21/9, and consequently reduced the expression
level (Fig. 6a and b) and nuclear translocation of Snail
(Fig. 6c). In order to explore sequestering of snail into
cytoplasm, we performed nuclear and cytoplasmic ex-
traction of cells after the overexpression of miR-449a.
Western blot analysis further confirmed that the
transfection with miR-449a had inhibited the nuclear
accumulation of snail (Fig. 6d).
Discussion
Although deregulation of miRNAs has been observed in
various types of human cancer, the molecular mechanisms
by which miRNAs modulate the process of carcinogenesis
are still unclear. In this study, we observed that down-
regulation of miR-449a is a frequent event in HCC tis-
sues, especially in those with the PVTT. Low-level
expression of miR-449a was significantly associated
with a more aggressive tumour phenotype and was
shown to be a strong and an independent predictor of
short disease-free survival for patients with HCC. In
functional studies, reintroduction of miR-449a dramat-
ically repressed HCC cell colony formation, migration
and invasion in vitro and tumour metastasis in vivo.
These findings suggest that miR-449a plays a critical
role in the invasive and/or metastatic potential of HCC.
The documents also reported that the miR-34 that
shares the same seed sequence with miR-449 is tumor-
suppressive and methylated in lung cancer [30]. And
the function of miR-449 in cancer is further supported
by experiments in several cancer cell lines in which
Fig. 4 Overexpression of miR-449a in Huh7 and LM9 cells reverses epithelial mesenchymal transfer. a Expression of epithelial markers and mesenchy-
mal markers were compared by western blot analysis between miR-control-Huh7, miR-control-LM9 and miR-449a-Huh7, miR-449a-LM9 cells. α-tubulin was
used as a loading control. bmiR-449a overexpression enhanced the mRNA level of E-cadherin in hepatoma cells. **P< 0.01. c The antagonism of endogen-
ous miR-449a promoted the EMT of hepatoma cells. HepG2 cells were transfected with anti-miR-449a or its control (anti-miR-NC) for 72 h
and analyzed by immunoblotting. α-tubulin was used as a loading control. d Immunohistochemistry staining showed a decreased expres-
sion of fibronectin and vimentin and an increased expression of E-cadherin and β-catenin in tumour tissues originating from miR-449a-
Huh7 cells, compared with that originating from miR-control-Huh7 cells. Scale bar: 50 mm
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miR-449 induces G1 arrest, apoptosis, and senescence
by regulation of a series of key factors in cell cycle and
apoptosis [16, 18, 31, 32]. These results indicate that
miR-449a regulates tumor growth as a tumor suppres-
sor, which could partially explain the correlation be-
tween low expression of miR-449a and poor prognosis.
The distinguishing feature of metastasis and invasive
growth is the transition of tumour cells from an epithelial
to a mesenchymal morphology, known as the epithelial–
mesenchymal transition (EMT). EMT who is character-
ized by the decrease of epithelial marker, increase of
mesenchymal markers, change of morphology, loss of
cellular adhesion and enhancement of cell motility ap-
pears to be a key event in tumor invasion and metastasis
[33]. The expression of EMT-associated markers are been
regulated by multiple transcription factors, such as Snail,
Twist and Zeb [34]. Recently, some studies have docu-
mented the involvement of EMT in HCC progression,
including the loss of E-cadherin and the gain of Snail
[35, 36]. To date, several deregulated miRNAs (miR-
101, miR-124 and miR-148a) have been shown to regu-
late EMT in HCC [6, 7, 37]. In this study, we found
that miR-449a is downregulated in HCC, especially in
tissues with the PVTT. The inhibition of miR-449a in
LO2 significantly promoted the transition of cells from
an epithelial to a mesenchymal morphology. And the
reintroduction of miR-449a into Huh7 and LM9 cells
reverses EMT, as shown by the enhanced expression of
the epithelial markers E-cadherin, α-catenin and β-
catenin, and decreased expression of the mesenchymal
Fig. 5 FOS and MET are targets of miR-449a. a Schematic illustration of the predicted miR-449a-binding sites in FOS and MET 3’-UTR. b FOS
and MET were targets of miR-449a. MiR report constructs, containing a wildtype and two mutated FOS and MET 3’-UTR, were co-transfected
into LM9 cells which were infected by miRcontrol-lentivirus or miR-449a-lentivirus. Relative repression of firefly luciferase expression was standardised
to a transfection control. Data of the reporter assays are the means ± SE of three independent experiments. c mRNA levels of FOS and
MET after miR-449a-induced expression in LM9 cells examined by real-time PCR. d Ectopic expression of miR-449a decreased endogenous
levels of FOS and MET protein in LM9 cells. LM9 cells were infected with either lentivirus-miR-control or lentivirus-miR-449a for 72 h. FOS
and MET expression was assessed by western blot. e The antagonism of endogenous miR-449a increased FOS and MET expression in the
HepG2 cell. Anti-miR-NC or anti-miR- 449a was transfected into HepG2 cells for 72 h and analyzed by immunoblotting. α-tubulin was
used as a loading control
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markers fibronectin, N-cadherin and vimentin. So we
identified miR-449a as a novel repressor on the EMT
and metastasis of HCC cells.
It has been reported that FOS and Met has been
shown to be overexpression in a variety of malignancies,
including HCC [38–40]. And c-fos can induce epithe-
lial–mesenchymal transition, which is associated with
loss of cell polarity, in mammary epithelial cells [41, 42].
The cell surface receptor tyrosine kinase c-Met is up-
regulated in a variety of tumors [43, 44]. The increased
c-Met signaling is associated with tumor growth and
metastasis in human cancers [45]. Our results show that
miR-449a inhibited the expression of FOS and Met by
binding to 3’UTR and suppressed the downstream
signaling. These observations are in accord with those of
Skawran Britta and colleagues, who reported miR-449
binds c-Met mRNA to reduce its levels [27]. And Wang
et al. also found that MicroRNA-449a is downregulated
in non-small cell lung cancer and inhibits migration and
invasion by targeting c-Met [20]. So the downregulation
of miR-449a has been regarded as the mechanism which
is responsible for the abnormal activation of c-Met.
It is known that the loss of E-cadherin expression has
the important role in the EMT and metastasis of tumor
cells. And the loss of E-cadherin expression may result
from transcription suppression by Snail accumulation or
by the promoter hypermethylation of E-cadherin gene
[28, 46]. Here we showed that miR-449a repressed the
activated phosphorylation of AKT and the inhibitory
phosphorylation of GSK-3α/β, and consequently re-
duced the nuclear accumulation of Snail and enhanced
E-cadherin expression. Interestingly, miR-449a may
relieve E-cadherin from transcriptional repression by
targeting Met/Snail signaling.
Conclusions
In conclusion, our data suggest that downregulation of
miR-449a plays an important role in HCC cell metastasis,
and that miR-449a could be employed as a new prognostic
marker and/or as an effective therapeutic target for HCC.
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Fig. 6 MiR-449a regulates AKT/GSK-3α/GSK-3β/Snail signaling and subcellular location of Snail. a miR-449a inhibited AKT/GSK-3α/GSK-3β/
Snail signaling in Huh7 cells. b miR-449a repressed the expression of Snail in LM9 cells. c miR-449a reduced the nuclear accumulation of
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immunofluorescent staining. Scale bar, 40 μm. d Expression of snail was compared by western blot analysis nuclear and cytoplasmic
extraction of miR-control-Huh7 and miR-449a-Huh7 cells. LaminB was used as a loading control
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Additional file 3: Figure S1. Cell invasion was evaluated using a Matrigel
invasion chamber. LM9 and Huh7 cells were infected by miR-control-
lentivirus and miR-449a-lentivirus, respectively, or transfected with
siFOS and siMET. All cells were subjected to a Matrigel invasion
assay with fetal bovine serum as chemoattractant. Invasive cells
were fixed and stained with crystal violet. The inserts were treated
with 10 % acetic acid and the absorbance was measured. Both
overexpression of miR-449a and knockdown of FOS and MET clearly
inhibited the invasion of LM9 and Huh7 cells. Data are the means
±SD of three independent experiments. *p < 0.05, **p < 0.01. Scale
bar: 100 mm. (TIFF 2444 kb)
Additional file 4: Figure S2. Enforced expression of miR-449a in
HCC cell line inhibits the mRNA and protein levels of Notch1. (A)
Enforced overexpression of miR-449a in Huh7 cells decreases endogenous
levels of Notch1 protein. Huh7 cells were infected with Mock, lent-miR-ctr
or lenti-miR-449a for 72 hours. Notch1 expression was assessed by
Western blot. (B) MiR report constructs containing a wild-type and 2
mutated Notch1 3’UTRs were transfected into Huh7 cells, respectively.
Relative repression of firefly luciferase expression was standardized to
a transfection control. The reporter assays were performed 3 times
with essentially identical results. (C) The mRNA levels of Notch1 in
Mock, lent-miR-ctr or lenti-miR-449a Huh7 cells examined by Real-time
PCR. Lenti-miR-449a decreased the levels of Notch1 mRNA in Huh7 cells.
(D) Western blot assay showing protein levels of Notch1 after the
treatment of Mock, Anti-miRNC and anti-miR-449a in HepG2 cell line.
Anti-miR-449a could increase Notch1 expression in HepG2 cells.
(TIFF 718 kb)
Additional file 5: Table S3. Correlations between the levels of
miR-449a and the mRNA expression of FOS and Met in 77 HCCs.
(DOC 35 kb)
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